keyword
MENU ▼
Read by QxMD icon Read
search

Alendronate

keyword
https://www.readbyqxmd.com/read/29244683/insufficiency-fracture-occurring-3-years-after-union-of-an-intertrochanteric-hip-fracture-a-case-report
#1
Byung-Ho Yoon, Sung Bae Park
CASE: We present a rare case of insufficiency fracture at the level of the distal interlocking screw following union of an intertrochanteric hip fracture. A 74-year-old woman reported chronic thigh pain for 1 month. She had a history of an osteoporotic stable intertrochanteric fracture that was successfully treated with a short intramedullary nail 3.5 years prior. However, after union, the neck-shaft angle of the femur changed from 125° to 117°. She had been on alendronic acid therapy to prevent a secondary osteoporotic fracture...
January 2017: JBJS Case Connector
https://www.readbyqxmd.com/read/29239219/multifunctional-redox-responsive-and-cd44-receptor-targeting-polymer-drug-nanomedicine-based-curcumin-and-alendronate-synthesis-characterization-and-in-vitro-evaluation
#2
Xue Dong, Shaohua Zou, Chunjing Guo, Kaili Wang, Feng Zhao, Huaying Fan, Jungang Yin, Daquan Chen
The traditional therapy of cancer has systemic side effects, and many cancers, such as human breast cancer and lung cancer easily metastasize to bones, leading to the formation of secondary tumours. This study was aimed at enhancing the anti-tumour effect of curcumin (CUR) and preventing tumour spread to the bone. A novel multifunctional redox-responsive and CD44 receptor targeting polymer-drug, poly alendronate-hyaluronan-S-S-curcumin copolymer (ALN-oHA-S-S-CUR) based CUR and alendronate (ALN) were synthesized successfully with the disulphide bond linker...
December 14, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29236162/bisphosphonates-prevent-age-related-weight-loss-in-japanese-postmenopausal-women
#3
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue
Decline of body weight with aging is a major risk factor for frailty, osteoporosis and fracture, suggesting that treatment for osteoporosis may affect body composition. Recently, we have shown that 5-year treatment with raloxifene prevented age-related weight loss, suggesting some other drugs for osteoporosis may also prevent a decrease in body weight with aging. The present study aimed to identify the relationship between bisphosphonate treatment and body composition markers. We measured bone mineral density (BMD), body composition, and bone remodeling markers in 551 Japanese postmenopausal women with bisphosphonate treatment, which included risedronate or alendronate treatment (BP-treatment group; N = 193) and without treatment by any osteoporosis drug (no-treatment group; N = 358) for 4-7 years (mean observation periods; 5...
December 13, 2017: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29233714/bi-layered-nanocomposite-bandages-for-controlling-microbial-infections-and-overproduction-of-matrix-metalloproteinase-activity
#4
J Anjana, Annapoorna Mohandas, S Seethalakshmy, Maneesha K Suresh, Riju Menon, Raja Biswas, R Jayakumar
Chronic diabetic wounds is characterised by increased microbial contamination and overproduction of matrix metalloproteases that would degrade the extracellular matrix. A bi-layer bandage was developed, that promotes the inhibition of microbial infections and matrix metalloprotease (MMPs) activity. Bi-layer bandage containing benzalkonium chloride loaded gelatin nanoparticles (BZK GNPs) in chitosan-Hyaluronic acid (HA) as a bottom layer and sodium alendronate containing chitosan as top layer was developed. We hypothesized that the chitosan-gelatin top layer with sodium alendronate could inhibit the MMPs activity, whereas the chitosan-HA bottom layer with BZK GNPs (240±66nm) would enable the elimination of microbes...
December 9, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29227547/a-network-meta-analysis-on-the-short-term-efficacy-and-adverse-events-of-different-anti-osteoporosis-drugs-for-the-treatment-of-postmenopausal-osteoporosis
#5
Gui-Feng Liu, Zong-Qiang Wang, Lin Liu, Bu-Tian Zhang, Ying-Ying Miao, Shao-Nan Yu
A network meta-analysis was conducted to compare the short-term efficacy and adverse events of different drugs for the treatment of postmenopausal osteoporosis (PMO), providing a more effective treatment for PMO. We initially searched through various databases like PubMed, Cochrane Library and EMBASE from inception till October 2016. All randomized controlled trials (RCTs) of drugs for the treatment of PMO were included for direct and indirect comparison. A combination of direct and indirect evidence of different inhibitors of antidiabetic drugs for treatment of PMO were considered for calculating the weighted mean difference (WMD) value or odd ratio (OR) value and to draw surface under the cumulative ranking (SUCRA) curves...
December 11, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29214794/retraction-paper-comparison-of-effects-of-alendronate-and-raloxifene-on-lumbar-bone-mineral-density-bone-turnover-and-lipid-metabolism-in-elderly-women-with-osteoporosis-by-iwamoto-j-et-al-yonsei-med-j-2008-49-1-119-128
#6
https://www.readbyqxmd.com/read/29214023/assessment-and-clinical-management-of-bone-disease-in-adults-with-eating-disorders-a-review
#7
REVIEW
Anne Drabkin, Micol S Rothman, Elizabeth Wassenaar, Margherita Mascolo, Philip S Mehler
Aim: To review current medical literature regarding the causes and clinical management options for low bone mineral density (BMD) in adult patients with eating disorders. Background: Low bone mineral density is a common complication of eating disorders with potentially lifelong debilitating consequences. Definitive, rigorous guidelines for screening, prevention and management are lacking. This article intends to provide a review of the literature to date and current options for prevention and treatment...
2017: Journal of Eating Disorders
https://www.readbyqxmd.com/read/29213055/inhibiting-mevalonate-pathway-enzymes-increases-stromal-cell-resilience-to-a-cholesterol-dependent-cytolysin
#8
Sholeem Griffin, Giulio Preta, Iain Martin Sheldon
Animal health depends on the ability of immune cells to kill invading pathogens, and on the resilience of tissues to tolerate the presence of pathogens. Trueperella pyogenes causes tissue pathology in many mammals by secreting a cholesterol-dependent cytolysin, pyolysin (PLO), which targets stromal cells. Cellular cholesterol is derived from squalene, which is synthesized via the mevalonate pathway enzymes, including HMGCR, FDPS and FDFT1. The present study tested the hypothesis that inhibiting enzymes in the mevalonate pathway to reduce cellular cholesterol increases the resilience of stromal cells to PLO...
December 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29210434/nano-confinement-driven-enhanced-magnetic-relaxivity-of-spions-for-targeted-tumor-bioimaging
#9
Tuyen Duong Thanh Nguyen, Arunkumar Pitchaimani, Colin Ferrel, Ravindra Thakkar, Santosh Aryal
Superparamagnetic iron oxide nanoparticles (SPIONs) are highly biocompatible and have a versatile synthetic technique based on coprecipitation, reduction-precipitation, and hydrothermal methods, where Fe3+ and Fe2+ react in aqueous solutions; both these ions are present in our body and have clear metabolic pathways; therefore, they have attracted extensive research interest and development in the field of diagnostic imaging and therapy. However, most SPION-based clinical diagnostic contrast agents are discontinued due to severe pain, low transverse magnetic relaxivity range of 80-180 mM-1 s-1, shorter circulation half-life, and lack of disease specificity...
December 6, 2017: Nanoscale
https://www.readbyqxmd.com/read/29209196/commentary-association-between-alendronate-use-and-hip-fracture-risk-in-older-patients-using-oral-prednisolone
#10
COMMENT
Xiang-Dong Wu, Ke-Jia Hu, Wei Huang
No abstract text is available yet for this article.
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/29207226/-the-treatment-of-the-patient-presenting-with-chronic-kidney-disease-ckd-and-fragility-fractures
#11
REVIEW
Andrea Giusti, Maria Fusaro
Fragility fractures occur in all stages of chronic kidney disease (CKD) due to low bone mineral density and poor bone quality (namely osteoporosis), as well as in CKD-mineral and bone disorders (CKD-MBD). As in postmenopausal women and older adults, the prompt identification of CKD subjects with a history of fragility fractures is crucial in order to implement strategies to reduce the risk of new fragility fractures and their consequences. The treatment of severe osteoporosis for patients with stages 1-3 CKD should not differ from patients without CKD, while clinical decisions and pharmacological treatments in subjects with stages 4-5/5D CKD differ greatly, being more tricky and challenging...
December 5, 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/29204959/insights-into-the-bisphosphonate-holiday-a-preliminary-ftiri-study
#12
A L Boskey, L Spevak, Y Ma, H Wang, D C Bauer, D M Black, A V Schwartz
Bone composition evaluated by FTIRI analysis of iliac crest biopsies from post-menopausal women treated with alendronate for 10 years, continuously or alendronate for 5 years, followed by a 5-year alendronate-holiday, only differed with the discontinued biopsies having increased cortical crystallinity and heterogeneity of acid phosphate substitution and decreased trabecular crystallinity heterogeneity. INTRODUCTION: Bisphosphonates (BP) are the most commonly used and effective drugs to prevent fragility fractures; however, concerns exist that prolonged use may lead to adverse events...
December 5, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/29199359/risk-of-venous-thromboembolism-among-users-of-different-anti-osteoporosis-drugs-a-population-based-cohort-analysis-including-over-200-000-participants-from-spain-and-the-uk
#13
E Martín-Merino, I Petersen, S Hawley, A Álvarez-Gutierrez, S Khalid, A Llorente-Garcia, A Delmestri, M K Javaid, T P Van Staa, A Judge, C Cooper, D Prieto-Alhambra
The venous thromboembolism risk among anti-osteoporotics is unknown. In this primary care study, the risk with other bisphosphonates [1.05 (0.94-1.18) and 0.96 (0.78-1.18)], strontium [0.90 (0.61-1.34) and 1.19 (0.82-1.74)], in the UK and Spain respectively, and denosumab [1.77 (0.25-12.66)] and teriparatide [1.27 (0.59-2.71)] in Spain, did not differ versus alendronate. INTRODUCTION: Most of the known adverse drug reactions described for anti-osteoporosis medication (AOM) have been described in studies comparing AOM users to non-users...
December 3, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/29197953/prolonged-use-of-alendronate-alters-the-biology-of-cranial-repair-in-estrogen-deficient-rats-associated-simultaneous-immunohistochemical-expression-of-tgf-%C3%AE-1-%C3%AE-er-and-bmpr1b
#14
Allan Fernando Giovanini, Giuliene Nunes de Sousa Passoni, Isabella Göhringer, Tatiana Miranda Deliberador, João Cesar Zielak, Carmem Lucia Muller Storrer, Thais Andrade Costa-Casagrande, Rafaela Scariot
OBJECTIVES: TGF-β1 is a cytokine that may induce both osteoneogenesis through Runx-2 or fibrosis via the transcription of α-smooth muscle actin (α-SMA). Because it has been previously known that alendronate increases the level of TGF-β1 and that under the usual condition of bone metabolism the estrogen may prevent the fibrotic effect of TGF-β1, the aim of this study was to evaluate if alendronate alters the cellular differentiation process post calvarial surgery in estrogen-deficient specimens...
December 2, 2017: Clinical Oral Investigations
https://www.readbyqxmd.com/read/29196083/the-good-and-the-bad-about-the-2017-american-college-of-physicians-osteoporosis-guidelines
#15
Violet Lagari, Tara Gavcovich, Silvina Levis
PURPOSE: The American College of Physicians (ACP) published a set of guidelines on how to prevent fractures in men and women with low bone density or osteoporosis. As the population ages, the overall risk of fractures increases, thus burdening the health care system. These guidelines review current evidence for osteoporosis management, providing an update to the previous 2008 ACP's guidelines. METHODS: The ACP put forth 6 recommendations addressing the complexities in osteoporosis management based on evidence available through October 2016 with a focus on bisphosphonates, calcium, vitamin D, and estrogen...
November 28, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29192423/bisphosphonates-for-paget-s-disease-of-bone-in-adults
#16
REVIEW
Luis Corral-Gudino, Adrian Jh Tan, Javier Del Pino-Montes, Stuart H Ralston
BACKGROUND: Bisphosphonates are considered to be the treatment of choice for people with Paget's disease of bone. However, the effects of bisphosphonates on patient-centred outcomes have not been extensively studied. There are insufficient data to determine whether reducing and maintaining biochemical markers of bone turnover to within the normal range improves quality of life and reduces the risk of complications. OBJECTIVES: To assess the benefits and harms of bisphosphonates for adult patients with Paget's disease of bone...
December 1, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29188452/bisphosphonates-hinder-osteoblastic-osteoclastic-differentiation-in-the-maxillary-sinus-mucosa-derived-stem-cells
#17
Jun Zhang, Jaesuh Park, Jung-Woo Lee, Yong-Dae Kwon, Eun-Cheol Kim
OBJECTIVES: Although bisphosphonates (BPs) are known to be associated with osteonecrosis of the maxilla, the precise effects of BPs on bone metabolism in human maxillary sinus mucosal cells (HMSMCs) are not yet known. The purposes of this study were to examine the effects of the BPs zoledronate (ZOL) and alendronate (ALN) on osteoblastic and osteoclastic differentiation in HMSMCs and to investigate the signaling pathways involved. MATERIALS AND METHODS: The effects of ZOL and ALN were assessed for osteoblast differentiation by alkaline phosphatase (ALP) activity, alizarin red staining, and RT-PCR for genes encoding Runx2 and osterix...
November 30, 2017: Clinical Oral Investigations
https://www.readbyqxmd.com/read/29186901/live-fluorescent-staining-platform-for-drug-screening-and-mechanism-analysis-in-zebrafish-for-bone-mineralization
#18
Jung-Ren Chen, Yu-Heng Lai, Jhih-Jie Tsai, Chung-Der Hsiao
Currently, drug screening relies on cell-based experiments or on animal models to confirm biological effects. The mammalian system is considered too time-consuming, expensive and complex to perform high-throughput drug screening. There is a gap between in vitro cell-based models and the in vivo mammalian models. The zebrafish is an ideal model that could link preclinical toxicity screening with the drug development pipeline. Taking advantage of a highly conservative genomic, rapid development, large number of offspring, low cost and easy manipulation, zebrafish has been considered an excellent animal model for disease-based drug screening...
November 27, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29179892/update-on-osteoporosis-treatment
#19
REVIEW
Xavier Nogués, Daniel Martinez-Laguna
Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non-vertebral fractures where secondary prevention is highly important...
November 24, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29127845/highly-sensitive-determination-of-alendronate-in-human-plasma-and-dialysate-using-metal-free-hplc-ms-ms
#20
Miho Yamada, Xiao-Pen Lee, Masaya Fujishiro, Ken Iseri, Makoto Watanabe, Hiroshi Sakamaki, Naoki Uchida, Takaaki Matsuyama, Takeshi Kumazawa, Haruo Takahashi, Akira Ishii, Keizo Sato
A highly sensitive method was developed for the analysis of alendronate in human plasma and dialysate using MonoSpin™ SAX(®) extraction and metal-free high-performance liquid chromatography (HPLC)-tandem mass spectrometry (MS/MS) following methylation with trimethylsilyldiazomethane. The chromatographic separation of the derivatives for alendronate and alendronate-d6 was achieved on an L-column2 ODS metal-free column (50 mm  ×  2 mm i.d., particle size 3 µm) with a linear gradient elution system composed of 10 mM ammonium acetate (pH 6...
November 6, 2017: Legal Medicine
keyword
keyword
27344
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"